Name

BBVP-M

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for BBVP-M

Name

Alternate Names

Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039

Abbreviations

MTX

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

740
000740

Primary Site

Acute lymphoblastic leukemia (ALL)
Bladder cancer
Breast
Gestational trophoblastic cancer
head & neck cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Primary CNS lymphoma

Histology

None

Remarks

FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.

Coding

This drug should be coded

Name

Alternate Names

Alti-Prednisone
Alto-Pred
Ancortone
Apo-Prednisone
Colisone
Cortan
Dacortin
Delta-Dome#
Deltasone
Deltra
Fernisone Buffered
Keysone
Liquid Pred
Meticorten
Novo-Prednisone
Orasone
Panasol
Paracort#
Prednicen M
SK-Prednisone
Sterapred DS
Ultracorten
Winpred

Abbreviations

PDN
PRD
PRED

Category

Hormones and hormonal mechanisms

Subcategory

Glucocorticoid

NSC Number

10023
010023

Primary Site

Prednisone is used in regimens to treat multiple sites and histologies

Histology

None

Remarks

Code Prednisone when it is part of a drug regimen.

Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.

Coding

Please see remarks for additional information

Name

Alternate Names

Blenoxane
Bleo
Bleo-Cell
Bleo-S
Bleomycin for Injection
Bleomycin sulfate
Oil Bleo

Abbreviations

BLE
BLEO
BLM

Category

Chemotherapy

Subcategory

Antitumor antibiotic

NSC Number

125066

Primary Site

Squamous cell cancers

Histology

None

Remarks

FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021

Abbreviations

BCNU

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

409962

Primary Site

Brain
Hodgkin Lymphoma
Kidney cancer
Multiple myeloma
Non-Hodgkin lymphoma

Histology

None

Remarks

Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)

Coding

This drug should be coded
Glossary